Glasgow, Scotland, 19th May 2016 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, welcomes the final instalment of Lord Jim O’Neill’s Review on Antimicrobial Resistance (AMR), published today.
Lord Jim O’Neill’s global Review on AMR sets out its final recommendations, providing a comprehensive action plan for the world to prevent drug-resistant infections and defeat the rising threat of superbugs – something that could kill 10 million people a year by 2050, the equivalent of 1 person every 3 seconds, and more than cancer kills today. Building on eight interim papers, this is the final report from Lord O’Neill’s Review, established by the UK Prime Minister David Cameron in 2014 to avoid the world being “cast back into the dark ages of medicine”.
Dr Miroslav Ravic, CEO of MGB Biopharma, said: “We are pleased the major problem of antimicrobial resistance is receiving the attention it clearly deserves. The need for novel and differentiated products to tackle antimicrobial resistance is clear and requires new and radical thinking from a broad range of stakeholders. MGB Biopharma is one of the very few companies developing a truly novel class of antibiotics designed to tackle the infections caused by multi-resistant bacterial pathogens. Our lead candidate MGB-BP-3 has the potential to become one of the first truly novel classes of antibiotic, with no prior resistance, to be approved in over 10 years.”
Raymond Spencer, CFO of MGB Biopharma, said: “The figures contained in Lord O’Neill’s review, and in particular the potential human cost of not addressing antibiotic resistance, are alarming. We welcome the recommendations contained in this report. We hope that innovative companies like MGB can benefit from the Global AMR Innovation fund and ‘market entry rewards’ proposed by Lord O’Neill to encourage the supply of new antibiotics.“
MGB Biopharma has recently successfully completed a Phase I clinical trial of an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile infections. MGB-based anti-infectives have the potential to deliver significant advantages over current approaches based on broad, bactericidal activity against multi-drug resistant Gram-positive pathogens. Other compounds from the platform have shown the potential to treat infection caused by Gram-negative, viral, fungal and parasitic organisms.
While pursuing its clinical development activities MGB Biopharma is now evaluating partnering and funding sources for its lead compound MGB-BP-3, which has the potential to offer a clear differentiated treatment option for patients with life threatening infections caused by resistant Clostridium difficile.
Lord Jim O’Neill’s global Review on AMR sets out its final recommendations, providing a comprehensive action plan for the world to prevent drug-resistant infections and defeat the rising threat of superbugs – something that could kill 10 million people a year by 2050, the equivalent of 1 person every 3 seconds, and more than cancer kills today. Building on eight interim papers, this is the final report from Lord O’Neill’s Review, established by the UK Prime Minister David Cameron in 2014 to avoid the world being “cast back into the dark ages of medicine”.
Dr Miroslav Ravic, CEO of MGB Biopharma, said: “We are pleased the major problem of antimicrobial resistance is receiving the attention it clearly deserves. The need for novel and differentiated products to tackle antimicrobial resistance is clear and requires new and radical thinking from a broad range of stakeholders. MGB Biopharma is one of the very few companies developing a truly novel class of antibiotics designed to tackle the infections caused by multi-resistant bacterial pathogens. Our lead candidate MGB-BP-3 has the potential to become one of the first truly novel classes of antibiotic, with no prior resistance, to be approved in over 10 years.”
Raymond Spencer, CFO of MGB Biopharma, said: “The figures contained in Lord O’Neill’s review, and in particular the potential human cost of not addressing antibiotic resistance, are alarming. We welcome the recommendations contained in this report. We hope that innovative companies like MGB can benefit from the Global AMR Innovation fund and ‘market entry rewards’ proposed by Lord O’Neill to encourage the supply of new antibiotics.“
MGB Biopharma has recently successfully completed a Phase I clinical trial of an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile infections. MGB-based anti-infectives have the potential to deliver significant advantages over current approaches based on broad, bactericidal activity against multi-drug resistant Gram-positive pathogens. Other compounds from the platform have shown the potential to treat infection caused by Gram-negative, viral, fungal and parasitic organisms.
While pursuing its clinical development activities MGB Biopharma is now evaluating partnering and funding sources for its lead compound MGB-BP-3, which has the potential to offer a clear differentiated treatment option for patients with life threatening infections caused by resistant Clostridium difficile.
